Moderna, Inc. (MRNA)
NASDAQ · Health Care · market cap 25.28B
Share price
$220.83
At the last nightly close
Intrinsic value
Suspended
The filed accounts describe the company before the break. A value returns with the first annual report filed after it.
Margin of safety
Suspended
Valuation suspended: the price broke +177% on 2026-08-19 (spin-off, corporate action or news the accounts do not contain yet) after the accounts it rests on.
EV / EBIT
n/a
Not ranked: negative ebit.
How these numbers are computed
The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above starts from the lower of the first two; the Graham Number never enters it.
The frame gives no credit for growth unless the company has earned it: only a return on invested capital that has beaten the cost of capital year after year earns a growth credit, and that credit is capped. A company that compounds will therefore usually read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.
The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.
Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-08-23.
Key metrics
Market position
Annual financials
| Period | Revenue | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|
| 2025-FY | 1.92B | -3.07B | -2.82B | -7.26 | -2.08B |
| 2024-FY | 3.20B | -3.94B | -3.56B | -9.28 | -4.05B |
| 2023-FY | 6.75B | -4.24B | -4.71B | -12.33 | -3.83B |
| 2022-FY | 18.88B | 9.42B | 8.36B | 21.26 | 4.58B |
| 2021-FY | 18.47B | 13.30B | 12.20B | 28.29 | 13.34B |
Filed figures from SEC EDGAR, in the reporting currency.
Next earnings
Recent news
- Moderna Slides 4.5% as Investors Appear to Pause Ahead of Key Near-Term Catalysts | Quiver Quantitativequiverquant.com
- Moderna (MRNA) Research Report - StockStorystockstory.org
- MRNA: Moderna Inc - Stock Price, Quote and Newscnbc.com
- Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Moversyoutube.com
- Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Moversfinance.yahoo.com
Headlines link to their source. Sperio does not republish article text.
The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on MRNA.
Run the board on MRNA10 free analyses · no signup, no card
This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.